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IMPORTANCE Acquired resistance to anti-EGFR therapy (epidermal growth factor receptor)
is frequently due to RAS and EGFR extracellular domain (ECD) mutations in metastatic
colorectal cancer (mCRC). Some anti-EGFR–refractory patients retain tumor EGFR
dependency potentially targetable by agents such as Sym004, which is a mixture of
2 nonoverlappingmonoclonal antibodies targeting EGFR.
OBJECTIVE To determine if continuous blockade of EGFR by Sym004 has survival benefit.
DESIGN, SETTING, AND PARTICIPANTS Multicenter, phase 2, randomized, clinical trial
comparing 2 regimens of Sym004with investigator’s choice fromMarch 6, 2014, through
October 15, 2015. Circulating tumor DNA (ctDNA) was analyzed for biomarker and tracking
clonal dynamics during treatment. Participants had wild-type KRAS exon 2mCRC refractory
to standard chemotherapy and acquired resistance to anti-EGFRmonoclonal antibodies.
INTERVENTIONS Participants were randomly assigned in a 1:1:1 ratio to Sym004, 12 mg/kg/wk
(arm A), Sym004, 9mg/kg loading dose followed by 6mg/kg/wk (arm B), or investigator’s
choice of treatment (arm C).
MAIN OUTCOMES ANDMEASURES Overall survival (OS). Secondary end points included
preplanned exploratory biomarker analysis in ctDNA.
RESULTS A total of 254patientswere randomized (intent-to-treat [ITT] population) (median age,
63 [range, 34-91] years; 63%male; n = 160).MedianOS in the ITTpopulationwas 7.9months
(95%CI, 6.5-9.9months), 10.3months (95%CI, 9.0-12.9months), and9.6months (95%CI,
8.3-12.2months) for armsA,B, andC, respectively (hazard ratio [HR], 1.31; 95%CI,0.92-1.87 for
AvsC; andHR,0.97;95%CI,0.68-1.40 forBvsC). The ctDNA revealedhigh intrapatient genomic
heterogeneity following anti-EGFR therapy. Sym004effectively targetedEGFRECD-mutated
cancer cells, andadecrease inEGFRECDctDNAoccurred in Sym004-treatedpatients.However,
this didnot translate into clinical benefit in patientswithEGFRECDmutations, likely owing to
co-occurring resistancemechanisms.A subgroupof patientswasdefinedby ctDNA (RAS/BRAF/
EGFRECD-mutationnegative) associatedwith improvedOS in Sym004-treatedpatients in armB
comparedwith armC (medianOS, 12.8 and7.3months, respectively).
CONCLUSIONS AND RELEVANCE Sym004 did not improve OS in an unselected population of
patients with mCRC and acquired anti-EGFR resistance. A prospective clinical validation of
Sym004 efficacy in a ctDNAmolecularly defined subgroup of patients with refractory mCRC
is warranted.
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P anitumumab and cetuximab are 2 anti-EGFR (epider-mal growth factor receptor) monoclonal antibodies(mAbs) approved for treatment ofRASwild-type (WT)
metastatic colorectal cancer (mCRC).1-3 However, response is
transient due to the emergence of acquired resistance.4-7 Our
research group and others previously elucidated themolecu-
larmechanisms responsible for treatmentprogression to anti-
EGFRmAbs.8-10 Alterations in components of the RAS signal-
ing pathway, together with mutations in the extracellular
domain (ECD) of the EGFR gene (OMIM 131550), are themost
common mechanisms of acquired resistance to EGFR block-
ade inmCRC.4,6,7 In addition, a specificmutation of theBRAF
geneat aminoacidposition600(BRAFV600E)hasbeendocu-
mented to be associatedwith poor prognosis in patients with
mCRC.1,11,12
A potential approach to overcome acquired resistance to
approvedanti-EGFRmAbs is treatmentwithmixturesofmAbs
targeting nonoverlapping epitopes of EGFR.13,14 Sym004 is a
mixture of 2 mAbs, futuximab and modotuximab, that bind
tononoverlappingepitopes inEGFRECDIII. Sym004hasbeen
extensively evaluated in preclinicalmodels and in early clini-
cal development.14,15 Binding of the Sym004 mAbs to EGFR
leads tohighly efficient receptor internalization anddegrada-
tion, which in turn leads to profound inhibition of cancer cell
growth.16,17 This novel synergisticmechanismof EGFR elimi-
nation results in more effective blockade of EGFR signaling
pathways and higher antitumor activity than that observed
with single mAbs.16,18
In a recent phase 1 study,15 Sym004was found to be well
tolerated at doses up to 12 mg/kg/wk, with grade 3 skin toxic
effects and hypomagnesemia as mechanism-based dose-
limiting toxic effects. Notably, Sym004 showed early signs of
clinical activity in an expansion cohort of 39 anti-EGFR anti-
bodypretreatedpatientswithmCRC.Tumorshrinkagewasob-
served in 44% of patients, and 13% achieved partial re-
sponses, providing a clear rationale for further exploring the
activity of Sym004 in mCRC.15
In the present study, we report safety and efficacy data
from treatment with 2 dose regimens of Sym004 or with in-
vestigator’s choice (IC)ofchemotherapyorbest supportivecare
(BSC) in a randomized phase 2 clinical trial in chemorefrac-
tory patientswithmCRCand acquired resistance to approved
anti-EGFR mAbs. As part of the planned biomarker analysis,
tumor circulating tumor DNA (ctDNA) assessment was used
to identify a biomarker-definedpatient population that could
obtain significant clinical benefit from Sym004 treatment.
Methods
Study Design and Participants
Sym004-05 was a multicenter, phase 2, randomized clinical
trial in patients with treatment-refractory mCRC and ac-
quired resistance to therapy with anti-EGFR mAbs. The trial
protocol is available at Supplement 1. The study was re-
viewed and approved by the ethics committee of all partici-
pating institutions. Informed consent was obtained from all
study participants.
Patients with histologically or cytologically confirmed
mCRC that was exon 2 KRASWT at the time of initial diagno-
sis and who gave written informed consent were screened
for enrollment to this trial. Includedpatientswere required to
have prior intolerance to or failure of standard chemotherapy
regimens including fluorouracil, oxaliplatin, and irinotecan,
and were allowed to have received bevacizumab or ziv-
aflibercept. Prior therapy with regorafenib was not permit-
ted. In addition, all included patients had acquired resistance
to prior therapy with a marketed anti-EGFR mAb, as defined
by having achieved either an objective partial response (PR),
complete response (CR), or stable disease for more than 16
weeks followedbydocumentedprogressive disease (PD) dur-
ing or within 6 months of completion of this therapy. In-
cludedpatientswere required to havemeasurable disease ac-
cording to Response Evaluation Criteria in Solid Tumors
(RECIST), andanEasternCooperativeOncologyGroup (ECOG)
performance status of 0 or 1.
Patients were randomly assigned in a 1:1:1 ratio to 1 of 3
treatment arms, 1 of 2 dose regimens of Sym004, 12 mg/
kg/wk (arm A) or 9 mg/kg loading dose followed by 6 mg/
kg/wk (arm B) compared with a control group, which in-
cluded IC of capecitabine, fluorouracil, or BSC (arm C).
Treatment continued until radiographically confirmed dis-
ease progression on standard imaging, unacceptable toxic ef-
fects, death, or thepatient or physiciandecided to stop.Doses
could bemodified tomanage treatment-related toxic effects.
Overall survival (OS), defined as time from randomiza-
tion todate of deathor censored at last dayof contact,was the
primary efficacy end point. Secondary end points included
safety; progression-free survival (PFS), defined as time from
randomization todateofdiseaseprogressionordeath fromany
cause; response rate; and exploratory biomarker analysis.
To establish a robust estimate of Sym004 survival ben-
efit, aminimumof 240patientswere to be randomizedbased
on 80% statistical power to differentiate assumedmedianOS
of 6months for arm C group19 and 9.2months for armA or B,
with a 2-sided level of significance of P = .121. The primary
analysiswas tobeperformedwhenat least 181 events (deaths)
Key Points
Question Does continuous blockade of EGFR (epidermal growth
factor receptor) by Sym004 (amixture of futuximab and
modotuximab) lead to a survival benefit in patients with anti-EGFR
refractory metastatic colorectal cancer?
Findings In this randomized clinical trial that included 254
patients, Sym004 did not improve survival compared with
investigators’ treatments of choice in the intent-to-treat
population. Preplanned circulating tumor DNA biomarker profiling
captured high intrapatient heterogeneity and identified a
Sym004-sensitive subpopulation with clinically meaningful
improvement of overall survival.
Meaning These findings provide the rationale for a prospective
clinical validation of Sym004 efficacy in a molecularly defined
subgroup of patients with acquired resistance to anti-EGFR
therapy.
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had been reported or 12months after the last patientwas ran-
domized in the trial, whichever occurred later. The data cut-
off was October 24, 2016. We used the Kaplan-Meier method
togeneratecurves forOSandPFS.Hazard ratios (HRs) for treat-
ment effectswere estimatedwith anunstratified Cox propor-
tional hazards model.
Baseline ctDNA profiles (Guardant360, version 2.9;
Guardant Health) were obtained from blood samples col-
lected from patients in the trial (eFigure 1 in Supplement 2).
Serial samples obtained prior to and after 3 weeks of treat-
ment were also analyzed for EGFR ECD mutation dynamics.
The ctDNA was amplified using droplet digital polymerase
chain reaction (ddPCR) Supermix for Probes with EGFR ECD
mutation assays (Bio-Rad). This ddPCR was then performed
according to themanufacturer’s protocol.Weperformed 3 in-
dependent ddPCR experiments for each of the point muta-
tions assessed and for each longitudinal time point. Frac-
tional abundances (%) were calculated as follows: fractional
abundance = (number ofmutations events/[number ofmuta-
tion + WT events]) × 100 and were Poisson corrected by
QuantaSoft analysis software (BioRad).
Results
BetweenMarch 6, 2014, andOctober 15, 2015, of 299 patients
screened,254were randomlyassigned, and thesemadeup the
intent-to-treat (ITT) population (Figure 1). The study popula-
tion was balanced at baseline (Table 1). Patients were heavily
pretreated: 72%, 78%, and 72% in arms A, B, and C, respec-
tively, had received at least 3 previous regimens.
MedianOS in the ITTpopulationwas 7.9 (95%CI, 6.5-9.9)
months, 10.3 (95%CI, 9.0-12.9)months, and 9.6 (95%CI, 8.3-
12.2)months for arms A, B, and C, respectively (HR, 1.31; 95%
CI, 0.92-1.87 for A vs C; and HR, 0.97; 95% CI, 0.68-1.4 for
B vs C) (Table 2 and eFigure 2 in Supplement 2). Median PFS
in the ITTpopulationwas2.8 (95%CI, 1.8-3.2)months,2.7 (95%
CI, 2.6-3.3)months, and 2.6 (95%CI, 1.4-3.1) months for arms
A, B, and C, respectively. Response rates for evaluable pa-
tients in the ITT populationwere 11 PRs (14.1%), 8 PRs (9.6%),
and 1 CR and 1 PR (2.9%) in arms A, B, and C, respectively
(eTable 1 in Supplement 2). Theunexpectedly longmedianOS
of 9.6months in the IC arm led to evaluation of potential fac-
tors that might explain this finding. It became evident that a
subgroup of patients (n = 30) had been subject to nonstan-
dardmedicalpractice in first- or second-line therapies thathad
an impact on the efficacy of rescue chemotherapy in the anti-
EGFR refractory setting aswell as in themolecular character-
ization of these patients (details provided in eMethods and
eTable2 inSupplement2). Thispopulationwasexcluded from
the genomic analysis.
Treatmentwith both regimens of Sym004 led to a higher
frequency and severity of adverse events (AEs) than treat-
ment administered topatients on the IC arm, and theSym004
regimenof 12mg/kg/wk(armA)wasmorepoorly toleratedthan
the Sym004 9 mg/kg loading dose followed by 6 mg/kg/wk
(arm B) dosing schedule (eTable 3 in Supplement 2). The
Sym004AEprofilewasconsistentwithotheranti-EGFRmAbs,
although the frequencyand severity of bothdermatologicAEs
(94.0% and 92.9% for arms A and B, respectively, compared
with 10.3% in the IC arm) and hypomagnesemia (68.7% and
56.0% for arms A and B, respectively, compared with 7.7% in
Figure 1. Study Enrollment FlowDiagram for PatientsWithMetastatic Colorectal Cancer
Included in the Sym004-05 Study
299 Assessed for eligibility
45 Excluded
38 Not meeting inclusion criteria
2 Declined to participate
5 Other reasons
254 Randomized
83 Sym004 12 mg/kg
83 Received allocated 
intervention
0 Did not receive allocated 
intervention
1 Lost to follow-up
81 Discontinued intervention 
(disease progression, other)
1 Ongoing
0 Not treated
83 Analyzed
0 Excluded from analysis
86 Sym004 9/6 mg/kg
84 Received allocated 
intervention
2 Did not receive allocated
intervention (death)
0 Lost to follow-up
83 Discontinued intervention 
(disease progression, other)
1 Ongoing
2 Not treated
85 Investigator’s choice
78 Received allocated 
intervention
7 Did not receive allocated 
intervention (withdrew 
consent)
0 Lost to follow-up
77 Discontinued intervention 
(disease progression, other)
1 Ongoing
7 Not treated
86 Analyzed
0 Excluded from analysis
85 Analyzed
0 Excluded from analysis
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the IC arm) were higher than those found with other ap-
proved anti-EGFR mAb therapies. In contrast, the frequency
of gastrointestinal AEs appeared to be lower thanhas been re-
ported for other anti-EGFRmAbs (51.8% and 48.8% for arms
AandB, respectively, comparedwith47.4%in ICarm).The fre-
quency of treatment-emergent AEs leading to study treat-
ment discontinuation (6.0% in armBvs 7.7% in armC) and re-
lated treatment-emergent AEs leading to study treatment
discontinuation (2.4% in armB vs 3.8% in armC)was not dif-
ferent in patients treatedwith the lower Sym004 dose and IC
(eTable 3 in Supplement 2).
Baseline ctDNA profiles of alterations in 70 genes (eFig-
ure 1 in Supplement 2)were obtained fromblood samples col-
lected from 193 patients in the trial. Genotyping of baseline
ctDNAcapturedhigh intrapatient genomicheterogeneity and
confirmedpreviously reportedmechanismsof acquired resis-
tance to cetuximab and panitumumab, including mutations
in RAS (29.5% of patients), EGFR ECD (25% of patients), and
BRAF V600E (6.7% of patients), as well as amplification of
ERBB2/HER2 andMET (eFigures 3 and4 in Supplement 2). In-
activation of APC and/or TP53 is an early event in the devel-
opment of CRC and the APC/TP53 highest mutant allele fre-
quency (MAF) alteration in a patient’s ctDNA can therefore
serve as an arbitrary marker for clonal mutations (present in
all tumor cells). ThemedianMAF for themostprevalentTP53/
APCalterationswas close to20%.ThemedianMAFs forKRAS,
NRAS, EGFR ECD and BRAF were much lower than 20%,
indicating that these mutations are primarily subclonal, al-
Table 2. Efficacy Data for the ITT Study Population and PopulationWith Biomarker Data
Study Group OS (95% CI), mo
1-Year Survival, No.
(95% CI) HR (95% CI)
ITT population (n = 254)
Sym004 12 mg/kg (n = 83) 7.9 (6.5-9.9) 37 (26-47) 1.31 (0.92-1.87)
Sym004 9/6 mg/kg (n = 86) 10.3 (9.0-12.9) 44 (33-54) 0.97 (0.68-1.40)
Investigator’s choice 9.6 (8.3-12.2) 40 (29-51) 1 [Reference]
Population with biomarker data
(n = 193)a
Sym004 12 mg/kg (n = 70) 7.7 (5.5-11.3) 38 (26-49) 1.03 (0.69-1.54)
Sym004 9/6 mg/kg (n = 67) 9.9 (7.1-12.9) 44 (32-56) 0.79 (0.52-1.20)
Investigator’s choice (n = 56) 8.5 (6.4-9.9) 27 (16-41) 1 [Reference]
Abbreviations: ITT, intent-to-treat;
HR, hazard ratio; OS, overall survival.
a Sixty-one patients are excluded
from this population, 31 due to lack
of biomarker data and 30 due to
treatment and OS data inconsistent
with the study population (see
Supplement 2 for more
information).
Table 1. Baseline Characteristics for the Intent-to-Treat Study Population
Characteristic
Arm A,
Sym004 12 mg/kg
(n = 83)
Arm B,
Sym004 9/6 mg/kg
(n = 86)
Arm C,
Investigator’s Choice
(n = 85)
Age, mean (SD)a, y 62 (10) 64 (10) 61 (11)
Sex, No. (%)
Male 52 (63) 54 (63) 54 (64)
Female 31 (37) 32 (37) 31 (37)
Race, No. (%)
White 72 (88) 75 (87) 73 (86)
Other or NA 11 (13) 11 (13) 12 (14)
ECOG performance status, No. (%)
0 33 (40) 35 (41) 35 (41)
1 50 (60) 50 (58) 50 (59)
2 0 1 (1)a 0
Tumor site, No. (%)
Right colon 12 (15) 10 (12) 9 (11)
Left colon/rectum 67 (81) 72 (84) 70 (82)
Prior mCRC treatments, No. (%)b
2 23 (28) 19 (22) 24 (28)
3 27 (33) 24 (28) 29 (34)
≥4 33 (40) 43 (50) 32 (38)
Prior anti-EGFR mAb therapies, No. (%)
Cetuximab only 55 (66) 54 (63) 53 (62)
Cetuximab and panitumumab 12 (15) 14 (16) 14 (17)
Panitumumab only 16 (19.3) 18 (21) 18 (21.2)
Time since last anti-EGFR mAb therapy,
mean (SD), d
78 (48) 80 (51) 72 (46)
Abbreviations: ECOG, Eastern
Cooperative Oncology Group;
EGFR, epidermal growth factor
receptor; mAb, monoclonal antibody;
mCRC, metastatic colorectal cancer;
NA, not available.
a Patient had an ECOG performance
status of 1 at screening and
therefore met eligibility criteria.
bAll patients received at least 1 prior
anti-EGFRmAb cancer therapy.
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though a subset of 10 patients harbored RASmutations at al-
lele frequencies above 20% (Figure 2A). Six EGFR ECDmuta-
tions (V441D,V441G, S464L,G465E,G465R, andS492R)were
themost frequent (eachpresent in ≥5%of patients, totally de-
tected in 25% of patients; Figure 2C and eFigure 5 in
Supplement 2). Patients with EGFR ECDmutations hadmore
genetic alterations (median number of alterations per pa-
tient, 14; interquartile range [IQR], 10.0-18.5) compared with
the full biomarker patient population (median, 9; IQR, 5-14)
(Figure 2C). The frequency and type of EGFR ECDmutations
varieddependingonprevious treatmentwithcetuximaborpa-
nitumumab (Figure 2B).6,7,20
As a predefined exploratory secondary objective of the
study, we next aimed to investigate ctDNA-defined molecu-
lar subgroups thatwouldpredict Sym004efficacy.A20%RAS
MAF cutoff accurately selected a subgroup of 10 patients in
which RAS ctDNA mutations and other mutations of ac-
quired resistance were virtuallymutually exclusive, suggest-
ingRAS clonality (Figure 2C and eFigure 10 in Supplement 2).
In thesepatients,RASmutationspotentiallyexistedat the time
of diagnosis, before the patient received cetuximab or pani-
tumumabtherapy. Inpreclinicalpatient-derivedxenograftCRC
models with RAS and BRAF V600E mutations, poor or lim-
itedSym004activitywasobserved, indicating that clonalmu-
Figure 2. Mutant Allele Frequency, Genetic Alterations, and Treatment GroupOutcomes for Patients Included in the Sym004-05 Study
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A, Mutant allele frequency (MAF) of APC+TP53, KRAS exons 2, 3, and 4, NRAS
exons 2, 3, and 4, BRAF V600E, and the EGFR extracellular domain (ECD)
mutations V441D, V441G, S464L, G465E, G465R, and S492R in the 193
patients analyzed. For patients with more than 1 alteration in the same gene,
only the highest MAF alteration for each gene is shown. Red lines denote the
medians, black bars denote the interquartile ranges, and the dotted line depicts
MAF = 20%. B, Top, fraction of EGFR-ECD positive patients (including the
6most frequent EGFR ECDmutations) grouped by last anti-EGFR treatment
received prior to enrolment. Bottom, number of patients with each of the
6 EGFR ECDmutations whowere treated with either cetuximab or
panitumumab as the last anti-EGFR treatment prior to study enrollment. C, Bar
graph depicting number of genetic alterations for each genetically profiled
patient, grouped by patients with EGFR ECDmutations to the left (box). The
oncoprint denotes the 6 individual most frequent EGFR ECDmutations, KRAS
mutations in exon 2, 3, or 4 at all MAFs (KRAS) and at MAF greater than 20%
(KRAS >20), NRASmutations in exon 2, 3, or 4 at all MAFs (NRAS) and at MAF
greater than 20% (NRAS >20),MET and ERBB2/HER2 gene amplifications
(defined as copy number >5), and BRAF V600E. Percentages denote the
percentages of patients harboring the defined alteration.
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tations in these genes caused resistance to Sym004, as is the
case for cetuximab and panitumumab (eFigure 11 in
Supplement 2). Basedon thesedata,weperformedanexplor-
atory analysis of efficacy in a genomically defined subpopu-
lation, which excluded patients with clonal RAS (MAF >20%)
and BRAF V600E mutation (named double-negative mCRC;
170patients; eTable 3 in Supplement 2). Results showedan in-
crease in OS for the Sym004 9/6 group (arm B) (11.9 vs 9.9
months) and a smaller increase in the Sym004 12 group (arm
A) (8.9vs 7.7months) comparedwith the subpopulationofpa-
tients with biomarker data. Overall survival in the IC popula-
tion (arm C) was unchanged (8.4 and 8.5 months in the sub-
populationanddouble-negativemCRCsubgroup, respectively).
Thus, this exploratory biomarker-defined analysis showedan
increase in median OS of 3.5 months in the double-negative
mCRC population of patients treated with Sym004 9/6 (arm
B; 11.9months) comparedwithpatients randomized to IC (arm
3; 8.4 months) (Figure 3A).
Figure 3. Survival and Other Characteristics ofMolecularly Defined Groups of Study PatientsWithMetastatic Colorectal Cancer (mCRC)
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A, Kaplan-Meier survival estimates for overall survival in patients with
double-negative mCRC, as defined in the Results section. B, Heat map showing
how the binding of different antibodies is affected by the different EGFR
extracellular domain (ECD) mutations; the effect on binding was determined as
the fold reduction in half maximal effective drug concentration (EC50) relative
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of treatment with Sym004; EGFR ECDmutation dynamics are highlighted for
2 patients (green and red), demonstrating an increase in MAF for 1 EGFR ECD
mutation and a decreasedMAF for 1 or more other EGFR ECDmutations from
week 1 to week 3. For each EGFR ECDmutation, the EGFR ECDMAFwas
normalized to the TP53MAF; ctDNA indicates circulating tumor DNA.
D, Kaplan-Meier survival estimates for overall survival in patients with
triple-negative mCRC, as defined in the Results section.
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We then investigated the role of EGFR ECDmutations as
abiomarkerofSym004activity.Preclinical studiesshowedthat
EGFR ECDmutations negatively affected the binding and ac-
tivityof cetuximab,panitumumab,andfutuximab,all ofwhich
bind to surface-exposed amino acids in the V441-S492 region
ofdomain III ofEGFR. The inhibitoryactivityofSym004,how-
ever, was partially rescued by the modotuximab component
of Sym004, which binds to a different region and retains full
binding andactivity toward themost frequentEGFRECDmu-
tations (Figure 3B and eFigures 6, 7, 8, and 9 in Supplement
2). Unexpectedly, the presence ofEGFRECDmutations in the
ctDNAofpatientswasnot linked to clinical benefit of Sym004
(eFigure 12 in Supplement 2). Themost plausible explanation
was the subclonal nature of the EGFR ECD mutations in the
patients and intrapatient heterogeneity (Figure 2C and eFig-
ure 3 in Supplement 2). To study themolecular basis of these
findings inmore detail, we sought to analyze the dynamics of
EGFR ECDmutations in blood from patients during Sym004
treatment. The percentage of EGFR ECD mutations de-
creased in the majority of patients treated with Sym004
(Figure3C), suggesting that subclones carryingEGFRECDmu-
tationsmight be targeted by themodotuximab component of
Sym004, as shown in the preclinical studies (Figure 3B and
eFigures 7, 8, and 9 in Supplement 2). However, this retained
activity did not translate into a clinically meaningful OS ben-
efit, likely owing to other co-occurring resistance mecha-
nisms (Figure 2C and eFigures 13, 14, and 15 in Supplement 2)
and subclonality of EGFR ECD mutations (eFigure 3 in
Supplement 2). Of note, in the 2 patientswho experienced an
increase in percentage of 1EGFRECDmutation in ctDNAdur-
ingSym004therapy,otherEGFRECDmutations thatwerecon-
comitantly detected in the same sample declined following
Sym004 therapy (Figure 3C).
Most notably, we found that the molecular heterogeneity
related to known resistance markers (which we defined as
the number of resistance alterations, including RAS, BRAF,
and EGFR ECD mutations and ERBB2/HER2 and MET
amplifications)21-23wasassociatedwithworseOS (eFigure 12 in
Supplement 2). This led us to postulate that the occurrence of
heterogeneous resistancemutations (includingEGFRECDmu-
tations) might pinpoint a subset of patients in which high ge-
nomic complexity due to previous chemotherapy and EGFR
blockade impairedeffectivenessof Sym004 treatment. To test
thishypothesis,weassessedoutcomes inpatientswithRAS less
than20%MAF,BRAFWT,andEGFRECDWT,whichwenamed
triple-negativemCRC(eTable4 inSupplement2).Wefoundthat
the triple-negativemCRCpopulation hadmarkedly prolonged
OS for Sym004 treatment arms: 12.8 (95%CI, 9.7-14.7)months
in theSym0049/6group (armB;n = 46) and 10.6 (95%CI, 6.8-
13.3) months in the Sym004 12 group (arm A; n = 47), com-
paredwith 7.3 (95%CI, 6.3-8.8)months in the IC group (armC;
n = 38) (Figure 3D and eTable 4 in Supplement 2).
Discussion
Sym004 is amixtureof2mAbs that targetnonoverlappingepi-
topes on domain III with more efficient mediated down-
modulation and subsequentdegradationof cell-surfaceEGFR
than the clinically approved antibodies cetuximab and pani-
tumumab, leading to more complete and durable pathway
inhibition.16,17 Here,we report safety and efficacy data froma
randomized,multicenter, phase 2 clinical trial of Sym004 in-
vestigating2Sym004dose regimensvs IC (capecitabine, fluo-
rouracil, or BSC) in patients with refractory mCRC and with
acquired resistance to anti-EGFR therapy.
In the ITT population, OSwas similar for all arms of treat-
ment. Based on historical data for last-line mCRC, the OS of
9.6months in the ICarm isnoteworthy.Currently, trifluridine/
tipiracil (TAS-102) and regorafenib are the only treatment op-
tions for last-line mCRC, based on an increase in median OS
in randomized clinical trials.24,25 While patients in the con-
trol arms in these 2 earlier studies received placebo, those in
thepresentSym004studyhadapotentiallyactivecontrol arm,
in which patients were able to receive capecitabine (68 pa-
tients), fluorouracil (13patients), orBSC (4patients). It is there-
fore plausible that a potential benefit of Sym004 in the ITT
population was masked by a control arm in which most pa-
tients received an active treatment.
Recently, EGFR ECDmutations have emerged as a poten-
tial novelmechanismof acquired resistance to cetuximaband
panitumumab in mCRC.6,7,10,26,27 In the present study, EGFR
ECD mutations were detected in approximately 25% of pa-
tients, and6ECDmutationswereparticularly abundant.A sig-
nificantly higher number of EGFR ECDmutations was found
in patients treated with panitumumab than in those treated
with cetuximab. The biology behind this apparent increased
frequency of EGFR ECD mutations in panitumumab-treated
patients is currently unknown, but lack of secondary effector
functions such as antibody-dependent, cell-mediated cyto-
toxic effects and the preference for monovalent binding of
panitumumab could be part of the explanation.
Whilepreclinical studies showedSym004efficacy inEGFR
ECD-mutated cells, anddynamic ctDNAanalysis showedade-
crease in EGFR ECD MAF following Sym004 treatment, the
presence of thesemutationswas not linked to clinical benefit
of Sym004 in thepresent trial. TheEGFRECDmutationswere
always subclonal and coexisted with other genetic altera-
tions related to anti-EGFR resistance, which suggests that al-
though theEGFRECD-mutated cells are targetedby Sym004,
Sym004-resistant clonal cell populations that fail to respond
toSym004existwithin the tumor.This findingprovidesaplau-
sible explanation for the lack of clinical benefit of Sym004 in
patientswithEGFRECDmutations.Ourdata thus suggest that,
in a subset of patients, treatmentwith the anti-EGFRantibod-
ies cetuximab and panitumumab results in the emergence of
extremely heterogenousmolecular landscapes inwhich sub-
clones with distinct mechanisms of resistance coexist. These
results are in agreementwithevidence that genomic complex-
ity following treatment pressure might be a poor prognostic
factor and severely limit the impact of subsequent lines of
treatment.28,29
Evaluation ofOS in the triple-negativemCRC) population
(patients with double-negative mCRC who are also without
EGFR ECD mutations) showed clinically meaningful in-
creases inmedianOS in both Sym004 treatment arms. In this
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exploratory analysis, the definition of triple-negative mCRC
appeared tobeaneffectivemethod toenrich thepatientpopu-
lation for responsiveness to Sym004.
Limitations
Apotential limitation of the study is that the treatment in the
control armwas by investigator’s choice, and 96%of patients
in the control armreceived chemotherapy. It is thereforeplau-
sible that a potential benefit of Sym004 in the ITTpopulation
wasmasked by a control arm inwhichmost patients received
an active treatment. Second, the study was designed to as-
sess OS in chemorefractory disease. However, patients were
allowed to have discontinued previous lines of therapy be-
causeof intolerancewithout failureof that chemotherapy, and
this potentially allowed for the recruitment of nonrefractory
patientswho could have benefited fromchemotherapy in the
control arm of the trial. Finally, although the increase in sur-
vival with Sym004 in the triple-negative population is prom-
ising, this is a retrospectivehypothesis-generatinganalysis that
has to be confirmed in a randomized clinical trial.
Conclusions
The results of this study showed that Sym 004 does not im-
proveOSor PFSwhenused in anunselected groupof patients
with mCRC and acquired EGFR resistance. In a hypothesis-
generating analysis, ctDNAprofiling identified a subset of pa-
tients (clonalRAS,BRAF, andEGFRECDWT) that gainedclini-
cally meaningful benefit from therapy with Sym004. These
findings provide the rationale for a prospective clinical vali-
dation of Sym004efficacy in amolecularly defined subgroup
ofpatients forwhomprioranti-EGFRtherapyhad failed.More-
over, these data support the use of liquid biomarker genomic
profiling toguide treatmentofpatientswithmCRCandto track
cancer evolution.
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